IL13 and glioblastoma: DTEGF13 is a bispecific immunotoxin consisting of DT390 fused to EGF and IL-13, made to target a range of solid tumors including glioblastoma, prostate, and pancreatic cancers, which overexpress receptors for both EGF and IL-13.